Last updated: February 15, 2026
Product Overview
NDC 50474-0598 corresponds to Xywav, a calicum, magnesium, and sodium-based oxybate formulation approved by the FDA in July 2021. Xywav is indicated for narcolepsy with cataplexy in adults, as well as idiopathic hypersomnia. It is marketed by Jazz Pharmaceuticals.
Market Landscape
The drug entered a competitive segment dominated by Sodium Oxybate (Xyrem), marketed by Jazz Pharmaceuticals. Both products share the same active moiety but differ in formulation and dosing strategies. Xyrem had annual US sales of approximately $1.1 billion in 2022 before Xywav's launch[1].
Market Size and Growth Trends
- Narcolepsy prevalence: Approx. 135,000 patients in the US, with around 70% receiving pharmacologic treatment[2].
- Idiopathic hypersomnia prevalence: Estimated at 20-30 cases per 100,000, with an underserved market but limited current treatment options.
- Xywav's market potential: Solidified by its improved safety profile and dosing flexibility compared to Xyrem.
- Market penetration: Given the niche indication, initial penetration is estimated at 10-15%, with growth contingent on prescriber awareness and insurance coverage.
Pricing Analysis
- Xywav's wholesale acquisition cost (WAC): Approximately $48,000 per year per patient[3].
- Comparison with Xyrem: Xyrem’s WAC is similar, around $60,000 annually.
- Reimbursement landscape: Insurance coverage, including Medicare and Medicaid, largely aligns with WAC, although patient out-of-pocket costs vary based on insurance plans and assistance programs.
Price Projections
- Short-term (next 12 months):
- Maintain current WAC levels at approximately $48,000 annually.
- Slight discounts or negotiated prices may reduce net price by 10–15%.
- Medium-term (1–3 years):
- Price stability expected; potential slight increases (~2-3%) aligned with inflation and R&D costs.
- Introduction of biosimilar or generic oxybate products could pressure prices downward after patent exclusivity expires (expected around 2030 for Xywav).
- Impact factors include formulary inclusion, prescriber switching costs, insurance reimbursement policies, and patient demand.
Competitive Risks and Opportunities
- Risks: Entry of generics post-patent expiration, payer restrictions, and limited patient pool could suppress prices.
- Opportunities: Expanding indications, increased awareness, and potential combination therapies may support higher utilization.
Legal and Regulatory Environment
No open patent infringement concerns currently threaten exclusivity. The Drug Enforcement Agency (DEA) classifies oxybate as a Schedule III controlled substance, complicating distribution and prescribing but not limiting pricing potential.
Summary
Xywav’s pricing remains aligned with current market standards for oxybate formulations. Its value proposition is heavily tied to safety improvements and dosage flexibility rather than price reduction. Market growth hinges on expanding approved indications and improving access.
Key Takeaways
- Xywav’s annual US wholesale price is approximately $48,000, with current market penetration limited by the niche indications.
- Competition from Xyrem and impending generic entrants after 2030 pose long-term price pressures.
- Short-term price stability is expected, with slight increases aligned with inflation and market dynamics.
- Market growth depends on prescriber adoption and expanded approvals.
FAQs
1. How does Xywav differ from Xyrem in pricing and formulation?
Xywav costs approximately $48,000 annually, slightly less than Xyrem. It contains a different salt formulation providing a broader safety profile and dosing flexibility.
2. What factors influence the future price of Xywav?
Patent expiration, generic competition, insurance reimbursement policies, and demand growth influence pricing.
3. When are generics expected to enter the market?
Post-2030, approximately 9 years after initial approval, assuming patent protections are not extended or extended.
4. Are there any legal challenges affecting its market?
No current patent or legal challenges threaten its exclusivity; however, DEA scheduling may impact distribution.
5. What is the potential market size for Xywav?
Approximately 70,000 to 100,000 patients in the US with narcolepsy and hypersomnia, with early market penetration estimates around 10-15%.
Sources
[1] IQVIA, 2022 US Prescription Data
[2] National Sleep Foundation, 2020
[3] Pricing transparency tools, April 2023
